3 “Strong Buy” Stocks from Wall Street – Week of 11/26

When a stock is rated as a “strong buy,” it typically means that analysts believe the stock has significant potential for growth and that the current price is undervalued. Analysts use a variety of methods to evaluate stocks, including financial analysis, market trends, and company performance. A “strong buy” rating is typically the highest rating an analyst will give to a stock.

Here are three “Strong Buy” stocks from Wall Street –

Biomea Fusion, Inc. – SYM: BMEA
Recent Price: $14.33
Price Target: $47.20
Firms with Buy Rating: Oppenheimer, Piper Sandler, Barclays
Description: Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

The 2 AI investing traps revealed [must read]

play button

Investor and entrepreneur James Altucher made millions during the crypto boom.

Many “experts” are now saying…

Artificial Intelligence opportunities could be even bigger.

But don’t believe the hype. Before you invest one penny in AI…

See James reveal the 2 AI investing TRAPS that will doom many investors…

Yes, making money from AI SHOULD be easy… But most AI investors will fall flat on their faces.

Because they don’t know the 2 AI investing TRAPS.

>>>See the 2 AI investing traps here now<<<


Lexeo Therapeutics, Inc. – SYM: LXEO
Recent Price: $12.27
Price Target: $20.80
Firms with Buy Rating: J.P. Morgan, RBC Capital, Stifel Nicolaus
Description: Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.


This is the exact moment when AI will throw off its shackles, instantly growing billions of times more intelligent than Einstein.

A two-time hedge fund manager is sharing a “Singularity Investor Playbook” you can use to position yourself at the forefront of this historic moment.



Rocket Lab USA, Inc. – SYM: RKLB
Recent Price: $4.40
Price Target: $7.39
Firms with Buy Rating: Cantor Fitzgerald, TD Cowen, Stifel Nicolaus
Description: Rocket Lab USA, Inc., a space company, provides launch services and space systems solutions for the space and defense industries. The company provides launch services, spacecraft design services, spacecraft components, spacecraft manufacturing, and other spacecraft and on-orbit management solutions; and constellation management services, as well as designs and manufactures small and medium-class rockets. It also designs, manufactures, and sells Electron small orbital launch vehicles and the Photon satellite platforms, as well as developing the Neutron 8-ton payload class launch vehicle; conducts remote launch activities; and designs and manufactures a range of components and subsystems for the Photon family of spacecraft and broader merchant spacecraft components. The company serves commercial, aerospace prime contractors, and government customers. Rocket Lab USA, Inc. was founded in 2006 and is headquartered in Long Beach, California.

[Revealed] Secret behind reclusive millionaire’s 7-year win streak

Imagine winning 97% of your trades over an 7-year period. Sounds impossible, right?

But that’s exactly what millionaire trader Jim Fink has achieved thanks to a simple trade that takes just 10 minutes each Tuesday.

No need to spend hours glued to your phone/screen watching and waiting for the perfect buy/sell moment…

He’s developed a unique approach that has allowed him to consistently win trade after trade, even in the most volatile markets.

Discover the secrets behind his strategy in this exclusive tell-all video!

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.